Scottish patients with the most aggressive form of viral hepatitis become first in UK to be offered routine NHS access to Hepcludex® (bulevirtide)
March 14, 2023Business Services
Monday 13 March 2023, London, UK – Gilead Sciences Ltd today announced that the Scottish Medicines Consortium (SMC) has become …
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023Business Services
KANSAS CITY, KANSAS and PRINCETON, NEW JERSEY – March 13, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing …
BRITISH LAND AND AUSTRALIANSUPER ANNOUNCE LIFE SCIENCES AMBITION AT CANADA WATER
March 13, 2023Business Services
13 March 2023
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
March 13, 2023Business Services
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled …
Richard Stedman rejoins ACG as the CEO of Engineering Division
March 13, 2023Business Services
ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce that …
Sanofi to acquire Provention Bio in $2.9bn deal
March 13, 2023Sales and Marketing
Sanofi has agreed to acquire Provention Bio as part of a $2.9bn deal that aims to improve the company’s portfolio …
Gilead Sciences wins $175m in ongoing HIV fraud case
March 13, 2023Sales and Marketing
Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies …
Nasal spray that relieves migraines in minutes approved by FDA
March 13, 2023Medical Communications
Pfizer is planning to launch a fast-acting nasal spray that can relieve pain from migraines in as little as 15 …
Horizon Therapeutics announces real-world treatment results for Dysthyroid Optic Neuropathy drug
March 13, 2023Medical Communications
Biopharma company Horizon Therapeutics has announced real-world treatment results for its Thyroid Eye Disease (TED) drug in patients with Dysthyroid …
Biotech centre focusing on gene therapies opens in Bristol, UK
March 10, 2023Medical Communications
A new state-of-the-art facility named the Clinical Biotechnology Centre (CBC) is opening in Bristol, UK. It cost approximately £10m to …
FDA makes unusual ‘misinformation’ comment on Lucira’s EUA for COVID-19 and flu test
March 10, 2023Sales and Marketing
The FDA has made a rare comment about what happened at Lucira Health’s Emergency Use Authorization (EUA) filing for its …
Acadia Pharmaceuticals awaits FDA decision for first-of-its-kind Rett syndrome drug
March 10, 2023Research and Development
Acadia Pharmaceuticals is aiming to follow in the footsteps of Reata Pharmaceuticals, who won approval for its novel drug to …
FDA committee supports Roche’s lymphoma treatment
March 10, 2023Medical Communications
A committee at the FDA have voted in favour of Roche’s Polivy antibody drug targeting untreated diffuse large B cell …
FlyPharma Europe, Vienna: 2023 conference officially launched
March 9, 2023Business Services
FlyPharma Europe, Vienna: 2023 conference officially launched FlyPharma Conferences is pleased to announce its seventh event in Europe, which …
MSD presents Phase 3 data for its Investigational Activin Signaling Inhibitor, in Adults with Pulmonary Arterial Hypertension on Background Therapy
March 9, 2023Business Services
LONDON, UK, March 6, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) today announced …
GSK’s RSV vaccine ready to launch
March 9, 2023Sales and Marketing
GSK has announced that it is ready to launch its respiratory syncytial virus (RSV) vaccine in the US at some …
Eli Lilly & Co’s Alzheimer’s disease drug fails to stop disease decline
March 9, 2023Research and Development
Eli Lilly & Co have today announced that its Alzheimer’s disease (AD) hopeful did not slow the progression of cognitive …
AstraZeneca shares positive results from Imfinzi trial
March 9, 2023Research and Development
Pharma giant AstraZeneca has shared positive results from a phase 3 trial on Imfinzi, its resectable non-small cell lung cancer …
Respiree gets FDA clearance for cardio-respiratory wearable
March 9, 2023Medical Communications
Respiree, a digital therapeutics start-up, has secured the 510(k) FDA clearance for its RS001 cardio-respiratory wearable. RS001 is a …
New clinical trial aims to find new endometriosis treatment
March 8, 2023Research and Development
A new clinical trial is set to begin shortly which will be a collaboration between the universities of Edinburgh, Aberdeen …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
